Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 180

1.

Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis.

Ciccia F, Guggino G, Rizzo A, Manzo A, Vitolo B, La Manna MP, Giardina G, Sireci G, Dieli F, Montecucco CM, Alessandro R, Triolo G.

Rheumatology (Oxford). 2015 Jul 15. pii: kev252. [Epub ahead of print]

PMID:
26178600
2.

Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease.

Guggino G, Orlando V, Cutrera S, La Manna MP, Di Liberto D, Vanini V, Petruccioli E, Dieli F, Goletti D, Caccamo N.

Immunol Lett. 2015 Aug;166(2):87-91. doi: 10.1016/j.imlet.2015.05.019. Epub 2015 Jun 5.

PMID:
26051682
3.

Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.

Ciccia F, Guggino G, Rizzo A, Bombardieri M, Raimondo S, Carubbi F, Cannizzaro A, Sireci G, Dieli F, Campisi G, Giacomelli R, Cipriani P, De Leo G, Alessandro R, Triolo G.

Clin Exp Immunol. 2015 Aug;181(2):219-29. doi: 10.1111/cei.12643. Epub 2015 Jun 3.

PMID:
25880879
4.

Invariant natural killer T cells treated with rapamycin or transforming growth factor-β acquire a regulatory function and suppress T effector lymphocytes.

Guggino G, Scottà C, Lombardi G, Dieli F, Sireci G.

Cell Mol Immunol. 2014 Apr 6. doi: 10.1038/cmi.2015.20. [Epub ahead of print] No abstract available.

PMID:
25849118
5.

Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset.

van Meijgaarden KE, Haks MC, Caccamo N, Dieli F, Ottenhoff TH, Joosten SA.

PLoS Pathog. 2015 Mar 24;11(3):e1004671. doi: 10.1371/journal.ppat.1004671. eCollection 2015 Mar.

6.

Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLA-E during active tuberculosis and express type 2 cytokines.

Caccamo N, Pietra G, Sullivan LC, Brooks AG, Prezzemolo T, La Manna MP, Di Liberto D, Joosten SA, van Meijgaarden KE, Di Carlo P, Titone L, Moretta L, Mingari MC, Ottenhoff TH, Dieli F.

Eur J Immunol. 2015 Apr;45(4):1069-81. doi: 10.1002/eji.201445193. Epub 2015 Feb 17.

PMID:
25631937
7.

Tumor-Infiltrating γδ T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment.

Lo Presti E, Dieli F, Meraviglia S.

Front Immunol. 2014 Nov 24;5:607. doi: 10.3389/fimmu.2014.00607. eCollection 2014. Review.

8.

Editorial: activation, functions, and generation of immunological memory in γδ T lymphocytes: lessons from nonhuman primates.

Dieli F, Mavilio D.

J Leukoc Biol. 2014 Dec;96(6):948-50. doi: 10.1189/jlb.4CE0714-364R. No abstract available.

PMID:
25452618
9.

γδ T cells as a potential tool in colon cancer immunotherapy.

Ramutton T, Buccheri S, Dieli F, Todaro M, Stassi G, Meraviglia S.

Immunotherapy. 2014;6(9):989-99. doi: 10.2217/imt.14.59. Review.

PMID:
25341120
10.

Vγ9 Vδ2 T lymphocytes activation as a novel approach to test efficacy of different bisphosphonates.

Rini GB, Sprini D, Migliaccio S, Basili S, Strollo R, Dieli F, Napoli N.

Endocrine. 2015 Feb;48(1):346-8. doi: 10.1007/s12020-014-0303-1. Epub 2014 Aug 6. No abstract available.

PMID:
25096911
11.

Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis.

Prezzemolo T, Guggino G, La Manna MP, Di Liberto D, Dieli F, Caccamo N.

Front Immunol. 2014 Apr 22;5:180. doi: 10.3389/fimmu.2014.00180. eCollection 2014. Review.

12.

The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-10 producing Th17 lymphocytes in patients with early rheumatoid arthritis.

Guggino G, Giardina A, Ferrante A, Giardina G, Schinocca C, Sireci G, Dieli F, Ciccia F, Triolo G.

Rheumatol Int. 2015 Jan;35(1):171-5. doi: 10.1007/s00296-014-3030-2. Epub 2014 May 3.

PMID:
24792332
13.

Efficacy and safety of γδT cell-based tumor immunotherapy: a meta-analysis.

Buccheri S, Guggino G, Caccamo N, Li Donni P, Dieli F.

J Biol Regul Homeost Agents. 2014 Jan-Mar;28(1):81-90.

PMID:
24750794
14.

CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.

Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R, Stassi G.

Cell Stem Cell. 2014 Mar 6;14(3):342-56. doi: 10.1016/j.stem.2014.01.009.

15.

Detection of natural killer T cells in mice infected with Rickettsia conorii.

La Manna MP, Torina A, Agnone A, Blanda V, Caracappa S, Alongi A, Di Marco V, Giudice E, Dieli F, Sireci G.

Transbound Emerg Dis. 2013 Nov;60 Suppl 2:80-5. doi: 10.1111/tbed.12143.

PMID:
24589105
16.

Targeting IL-6 signalling in early rheumatoid arthritis is followed by Th1 and Th17 suppression and Th2 expansion.

Guggino G, Giardina AR, Raimondo S, Giardina G, Sireci G, Dieli F, Peralta M, Alessandro R, Triolo G, Ciccia F.

Clin Exp Rheumatol. 2014 Jan-Feb;32(1):77-81. Epub 2014 Jan 14.

PMID:
24429356
17.

Butyrophilin 3A1 presents phosphoantigens to human γδ T cells: the fourth model of antigen presentation in the immune system.

Dieli F, Fadda R, Caccamo N.

Cell Mol Immunol. 2014 Mar;11(2):123-5. doi: 10.1038/cmi.2013.54. Epub 2013 Nov 25. No abstract available.

18.

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells.

Todaro M, Meraviglia S, Caccamo N, Stassi G, Dieli F.

Oncoimmunology. 2013 Sep 1;2(9):e25821. Epub 2013 Jul 29.

19.

An unconventional TRAIL to cancer therapy.

Chen HC, Dieli F, Eberl M.

Eur J Immunol. 2013 Dec;43(12):3159-62. doi: 10.1002/eji.201344105. Epub 2013 Nov 4.

PMID:
24136367
20.

Tumor and its microenvironment: a synergistic interplay.

Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G.

Semin Cancer Biol. 2013 Dec;23(6 Pt B):522-32. doi: 10.1016/j.semcancer.2013.08.007. Epub 2013 Sep 4. Review.

PMID:
24012661
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk